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Abstract
Different measures of rates of transfer of glucose during the peritoneal equilibrium test (PET), undertaken during peritoneal dialysis
(PD) might provide additional information regarding a patient’s risk of future cardiovascular mortality. This study aimed to characterize
the heterogeneity of dialysate glucose (DG) response phenotypes during the PET and compare the cardiovascular mortality rates
associated with the different phenotypes. Our cohort was derived from Henan peritoneal dialysis registry. A total of 3477 patients
initiating PD in 2007 to 2014 had the DG measured at 0, 2-hour and 4-hour (D0, D2, and D4 respectively) during the PET for
estimation of D2/D0 and D4/D0. Deaths mainly due to CVD within 2 years since the initiation of PD were defined as the outcome.
Latent class mixed-effect models were fitted to identify distinct phenotypes of the DG response during the PET. Multivariable
unconditional Logistic regression models with adjustment for cardiometabolic risk factors were used to compare the 2-year risk of
cardiovascular mortality among patients in the different latent classes. Three distinct DG response phenotypes during the PET were
identified. Those with consistently high D2/D0 and D4/D0 ratios had a 1.22 [95% confidence interval: 1.02, 1.35] excess risk of a
cardiovascular death within 2 years of commencing PD compared with patients with the lowest D2/D0 ratio and decreased D4/D0
ratio after adjustment for cardiometabolic risk factors. Consistently elevated D2/D0 and D4/D0 ratios during the PET are associated
with an increased risk of 2-year cardiovascular mortality independent of other cardiometabolic risk factors. In view of the potential bias
due to unmeasured confounders (eg, Family history of cardiovascular diseases, and dietary patterns), this association should be
further validated in other external cohorts.
Abbreviations: BMI = body mass index, CVD = cardiovascular disease, DG = dialysate glucose, eGFR = estimated glomerular
filtration rate, ESRD= end-stage renal disease, FG= fasting glucose, HGB= hemoglobin, HPDR=Henan peritoneal dialysis registry,
PD = peritoneal dialysis, PET = peritoneal equilibration test, SBP = systolic blood pressure, TC = total cholesterol, TP = total protein.
Keywords: cardiovascular disease, dialysate glucose, mortality, peritoneal dialysis, peritoneal equilibrium test
1. Introduction
Chronic kidney disease has been recognized as a worldwide
health problem.[1] End-stage renal disease (ESRD), in particular,
is associated with high premature mortality and a substantial
health economic burden.[2] It has been estimated that around 130
million Chinese adults have chronic kidney disease with dialysis
needed at some point in their lives.[3] The Chinese medical
insurance scheme has now increased its coverage, making
dialysis, especially peritoneal dialysis (PD), more affordable
among ESRD patients.[4] The leading cause of death among
people receiving PD care is cardiovascular disease (CVD).[5]
Patients receiving PD routinely undergo a peritoneal equilibra-
tion test (PET) to characterize the rate of transfer of solute and
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water across the peritoneal barrier.[6] The test yields 3 parameters
— the 4-hour dialysate to plasma ratio of creatinine (D/P
creatinine), the 4- to 0-hour dialysate glucose ratio (D/D0 glucose),
and the 4-hour ultrafiltration volume.[6] Although the PET results
can facilitate optimizing solute clearances, they aremoreoften used
to individualize PD prescriptions to maximize daily peritoneal
ultrafiltration.[7,8] Individuals with a faster rate of solute transfer
rate experience a higher risk of death, or transfer to hemodialysis, a
phenomenon thought to result from volume overload from the
challenges of fluid removal during continuous ambulatory PD.[9]
Previous research has explored the all-cause death and risk of
hospitalizationusing these3measurements at1 timepoint: 4-hours
after commencing PD.[10] It is not quite clear whether the
measurement response phenotypes during the PET are heteroge-
neous. Such heterogeneity could reflect different underlying
pathophysiological mechanisms. These dialysate glucose response
phenotypes reflect glucose metabolism status and their association
with future risk of cardiovascular death has not been fully
explored. Furthermore, investigating whether different dialysate
glucose response phenotypes during the PET represent distinct
cardiovascular risk profiles may contribute to an understanding of
the underlying pathophysiological pathways leading to cardiovas-
cular mortality.
This study now investigates the heterogeneity of dialysate
glucose phenotypes based on 2 time points (2-hour and 4-hour)
during the PET, and compares the cardiovascular death rate
between the identified latent classes. This study hypothesises that
there will be patients initializing PD who are at high risk of
cardiovascular mortality, who are not captured by the classical 1-
time measures of risk.
2. Material and methods
2.1. Data setting
We have used data from the Henan peritoneal dialysis registry
(HPDR) to develop and validate a CVD risk score.[11] Henan is a
province in the centre of China with the 2nd largest provincial
population. Briefly, as a longitudinal registry dataset, the HPDR
is operated under the auspices of the Department of Nephrology,
the First Affiliated Hospital of Zhengzhou University and
provides an independent audit and analysis of renal care in
Henan, China. Information was prospectively collected electron-
ically from all renal units across Henan during the study period.
Data arriving at the HPDR are subjected to an algorithm which
identifies suspicious values, which are then further verified and
corrected where necessary by contacting the renal unit.
2.2. Study population
This study was designed as a cohort study derived from HPDR,
which includes all adult patients aged 18 years and over who
commenced PD between 2007 and 2014 and who had at least 2
years follow-up. Following the standard approach to investigat-
ing “real” ESRD patients among all those receiving PD care, and
to avoid a reverse causality association between predictors and
outcome, patients who died, underwent transplant or whose
kidney function recovered within 90 days after initialization of
dialysis were excluded (n=16).
The study was conducted in compliance with the principles of
the Declaration of Helsinki and in accordance with GoodClinical
Practice guidelines. The protocol was reviewed and approved by
the by the Clinical Research Ethics Committee of the First
Affiliated Hospital of Zhengzhou University (Reference number:
KY-2017-22). All patients providing written informed consent
are informed that their anonymized records (with identifiable
information removed) may be used for research before study
entry.
2.3. PET test and dialysate glucose measurements
A standard PET was performed by trained nurses from HPDR;
dialysate samples were collected 0, 2-hour, and 4-hour after
commencement, and a blood sample was collected at 120
minutes. All blood and dialysate samples were analyzed within
24hours. Two dialysate glucose ratios: D2/D0 ratio (2-hour
dialysate glucose/0-hour dialysate glucose) and D4/D0 ratio (4-
hour dialysate glucose/0-hour dialysate glucose) were estimated
to quantify the dialysate glucose response phenotypes.
2.4. Covariables
All other comorbidity information, laboratory tests, and body
measurements were also performed using standard methods at
the date of first dialysis.
2.5. Statistical analysis
Latent class trajectory analysis was used to identify different
dialysate glucose response curve groups (phenotypes) during the
PET. The latent class mixed-effects model was specified with
linear, quadratic, and cubic time terms to model non-linear
change over time.[12] Coefficients were allowed to vary between
latent groups. In order to delineate the optimal number of latent
groups, we started with 1 group (equivalent to fitting a linear
mixed-effects model) and then increased the number of groups
one-by one.[13] We repeated this until group sizes remained
sufficiently large and the model’s Bayesian Information Criteria
stabilized.[9,14] After determining the best fitting model, each
individual was assigned to the glucose response curve group with
the highest membership probability.
Dialysate Glucose response curves were then refitted with
standard linear mixed-effects models including group member-
ship and its interaction with all terms within each of the glucose
curve groups. We then defined the cardiometabolic character-
istics (age, sex, body mass index [BMI], lipid profile, phosphate,
estimated glomerular filtration rate [eGFR], systolic blood
pressure [SBP] and diastolic blood pressure, respectively) of
study participants stratified by glucose response curve group.
Missing information was as follows: BMI (10.51%), phos-
phate (10.23%), albumin (9.92%), total protein (TP) (12.75%),
total cholesterol (TC) (14.53%), low density lipoprotein
(14.58%), high density lipoprotein (14.52%), triglyceride
(14.52%), fasting glucose (FG) (15.26%), SBP (2.26%), and
DBP (2.23%). We used multiple imputation to replace missing
values by using a chained equation approach based on all
candidate predictors. Fifteen imputed datasets were created for
missing variables that were then combined across all datasets by
using Rubin rule to obtain estimations.
Multivariable unconditional logistic regression models, with
adjustment for 2 sets of variables, were used to compare the risk
of cardiovascular mortality between latent classes. Model 1 was
adjusted for age and gender. Model 2 was additionally adjusted
for other variables presented in Table 1.
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All analyses were performed using STATA (STATA/SE 14.0
StataCorp, College Station, TX). All P-values were calculated
using 2-tailed tests and a P-value < .05 was taken to indicate
statistical significance.
3. Results
Three latent classes were identified, each including 6.7%, 11.8%,
and 81.5% of the cohort (Fig. 1). Average posterior group
membership probabilities were high, ranging between 0.81 and
Table 1
Demographic and cardiometabolic risk factor characteristics by dialysate glucose response phenotypes during the PET.
Overall Class 1 Class 2 Class 3
N 3477 2832 410 235
Male gender, n (%) 2051 (59.0) 1668 (59.5) 241 (57.5) 141 (55.6)
Cardiovascular disease, n (%) 1187 (34.2) 856 (30.2) 203 (49.5) 129 (54.8)
Taking antihypertensive treatment, n (%) 3087 (88.8) 2508 (88.6) 371 (90.7) 208 (88.4)
Age (yr) 48.0 (38.0, 59.0) 47.0 (38.0, 58.0) 52.0 (42.0, 61.0) 52.0 (44.0, 62.0)
Body mass index (kg/m2) 22.8 (20.8, 24.9) 22.7 (20.8, 24.8) 23.0 (21.0, 25.6) 22.9 (20.4, 25.1)
Total cholesterol (mmol/L) 4.5 (3.7, 5.2) 4.5 (3.7, 5.2) 4.8 (3.9, 5.3) 4.2 (3.6, 5.1)
Low density lipoprotein -cholesterol (mmol/L) 2.6 (2.0, 3.2) 2.6 (2.0, 3.2) 2.6 (2.1, 3.4) 2.2 (1.8, 3.0)
High density lipoprotein -cholesterol (mmol/L) 1.1 (1.0, 1.4) 1.1 (1.0, 1.4) 1.2 (1.0, 1.4) 1.1 (0.8, 1.3)
Triglyceride (mmol/L) 1.2 (1.0, 1.8) 1.2 (1.0, 1.8) 1.5 (1.0, 2.3) 1.5 (1.0, 2.0)
Systolic blood pressure (mm Hg) 142.0 (133.0, 155.0) 141.0 (132.0, 154.0) 146.0 (135.0, 157.0) 150.0 (136.0, 152.0)
Diastolic blood pressure (mm Hg) 86.0 (80.0, 94.0) 85.0 (80.0, 92.0) 90.0 (80.0, 95.0) 90.0 (80.0, 100.0)
Hemoglobin, g/L 94.0 (80.0, 107.0) 94.0 (80.0, 107.0) 98.0 (81.0, 112.0) 88.5 (78.0, 105.0)
Reticulocyte, % 43.4 (15.6, 69.1) 44.4 (20.0, 71.0) 26.0 (0.4, 56.0) 47.1 (1.2, 67.2)
Phosphate, mg/dL 1.7 (1.4, 2.1) 1.7 (1.4, 2.1) 1.7 (1.4, 2.0) 1.6 (1.2, 1.9)
Albumin, g/L 34.0 (30.2, 38.0) 33.9 (30.1, 38.0) 35.0 (31.2, 38.3) 34.0 (30.0, 37.3)
Total iron binding capacity , mmol/L 46.0 (36.2, 52.3) 47.6 (36.8, 52.6) 42.7 (34.0, 52.0) 34.6 (30.5, 40.4)
FeTIBC, mmol/L 24.6 (21.7, 39.4) 24.4 (21.7, 39.3) 25.9 (17.1, 39.0) 28.2 (22.7, 56.5)
Creatinine, mmol/L 872.3 (684.0, 1094.8) 883.3 (698.0, 1106.1) 783.0 (622.0, 1007.7) 867.0 (638.0, 1032.0)
estimated Glomerular Filtration rate, mL/min/1.73 m2 1.6 (0.5, 3.4) 1.6 (0.5, 3.5) 1.7 (0.6, 3.2) 1.0 (0.0, 2.7)
Transferrin, mg/dL 186.0 (100.0, 390.2) 185.0 (101.9, 386.3) 180.3 (68.1, 418.2) 263.5 (61.3, 763.1)
Total protein, g/L 58.0 (52.9, 62.8) 58.0 (52.8, 62.5) 59.4 (54.2, 66.1) 57.8 (51.8, 62.4)
Prealbumin, mg/L 314.0 (227.5, 382.5) 316.0 (237.0, 384.0) 309.5 (169.1, 385.3) 299.5 (188.0, 356.0)
Fasting glucose, mmol/L 4.8 (4.2, 5.4) 4.7 (4.2, 5.3) 5.1 (4.4, 6.5) 5.0 (4.4, 5.8)
Sodium, mEq/L 140.0 (137.0, 142.7) 140.0 (137.2, 143.0) 140.0 (137.0, 143.0) 139.0 (135.0, 141.5)
C-reactive protein, mg/dL 2.2 (1.0, 5.0) 2.1 (1.0, 5.0) 3.4 (2.5, 5.6) 2.6 (1.0, 7.7)
Binary variables are displayed as numbers (percentage) and continuous variables are displayed as median (interquartile range). Variables were compared between latent groups using Kruskal–Wallis tests for
continuous variables and x2 tests for categorical variables. For all differences, P-values were <.001.
PET = peritoneal equilibrium test.
Figure 1. Phenotypes of dialysate glucose ratios in the peritoneal equilibration test. Grey square dash-dot line, Latent class 1 (n=2832, 81.5%); grey diamond
dash-dot line, Latent class 2 (n=410, 11.8%); black circle dash-dot line, Latent class 3 (n=235, 6.7%). D0 = dialysate glucose at 0h, D2 = dialysate glucose at 2h,
D4 = dialysate glucose at 4h.
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0.91, indicating good discrimination between the groups. The
D2/D0 ratio varied between groups from 0.58 to 1.17, and the
D4/Do ratio ranged from 0.41 to 1.15, indicating considerable
heterogeneity.
Class 1 demonstrated the lowest D2/D0 and D4/Do ratios with
a dramatic decrease in glucose over the 2 time points. Class 3 had
the highest D2/D0 and D4/D0 ratios with stable estimations over
the 2 time points. Class 2 demonstrated a glucose decrease
response phenotype midway between Class 1 and Class 3 (Fig. 1).
Characteristics of study participants stratified by dialysate
glucose response curves are shown in Table 1. Class 1,
characterized by the lowest median age (47 years), the highest
proportion of males (59.5%), the lowest proportion of having
previously diagnosed CVD, the lowest median BMI, blood
pressure, triglyceride, FG and C-reactive protein, and the highest
median creatinine and prealbumin concentrations.
Patients in Class 2 had the highest proportion of prescribed
antihypertensive medication, the highest median TC, high density
lipoprotein cholesterol, hemoglobin (HGB), albumin, eGFR, TP,
FG, and C-reactive protein, and lowest median level of serum
creatinine.
Class 3 had the lowest proportion of males, the highest
proportion of having previously diagnosed CVD, the lowest
median level of TC, low density lipoprotein cholesterol, HGB,
phosphorus, Total iron binding capacity, eGFR, TP, prealbu-
min, and sodium, and the highest median level of blood
pressure, reticulocyte, Fe-total iron binding capacity, and
transferrin.
Absolute numbers and mortality rates with adjusted odd ratios
for 2-year cardiovascular mortality are provided in Table 2. The
2-year mortality rates were 10.3 (95% confidence interval: 9.2,
11.5) %, 10.0 (7.3, 13.3) %, and 15.7 (11.3, 21.0) % for Class 1,
Class 2, and Class 3, respectively. In the most adjusted model,
patients in Class 3 had a 22% elevated risk (odds ratio 1.22 [95
confidence interval: 1.09, 1.35]) of CVD death compared
with those in Class 1. Those in Class 2 had no excess CVD
mortality risk.
4. Discussion
This study identified heterogeneity in dialysate glucose response
to the PET test by a novel latent class trajectory analysis
approach. This study revealed 3 different phenotypes and was
able to associate them with the major long-term outcome, CVD
death. Class 3, when compared with Class 1 and had a 22%
increased CVD mortality, accompanied by a worse cardiome-
tabolic risk profile. This high-risk group had a stable estimation
of dialysate glucose over the PET and remaining at the highest
dialysate glucose/D0 estimations. Others have found that D4/D0,
is a marker for all-cause mortality and hospitalization and this is
in line with our study.[10]
The higher CVD mortality in patients in Class 3 might be
explained by their higher proportion of existing CVD, which has
been reported in other studies.[15,16] A further possible explana-
tion lies with their higher SBP: prior observation studies have
reported a strong association between high SBP and CVD
mortality.[15,17] Those in Class 3 also had worse kidney function,
as measured by eGFR, another risk factor for future CVD deaths,
as previously shown.[18] Risk factors generally reflecting worse
health status, like HGB and TP were also lower in Class 3, which
could also have contributed to the increased risk of CVD
mortality as observed in another study.[19–21]
In previous studies, the 1 time-point D4/D0 ratio has been used
to predict the future risk of long-term adverse outcomes.[22]
However, such measurements have limitations, as individual
patients with different dialysate glucose response trajectories can
still have similar values for some or several calculated curve
features. Therefore, instead of studying predefined curve
characteristics, we considered heterogeneity of change using a
data-driven approach. Latent class trajectory analysis allows the
investigation of change over time, while taking measurement
error into account. Compared with conventional approaches
assessing only mean growth curves, the latent class method is
suitable for revealing heterogeneous phenotypes, which may give
a more complete picture of associations.
It is important to bear in mind that the aim of this study was
not to derive the best prediction model or to determine optimal
cut-off values for the examined outcomes, but to find
associations that might not have been revealed using conven-
tional methods. We observed that different dialysate glucose
response phenotypes during PET are associated with CVD
death, which persist after adjustment for (eg, cannot be fully
explained by differences in) the cardiometabolic risk profile.
This suggests that dialysate glucose measurements at different
time points should be considered simultaneously to obtain a
more detailed picture of the individual risk of future CVD death.
Although the dialysate glucose response pattern was measured
and recorded by trained nurses from HPDR to ensure relatively
high validity, involvement of only a single recruitment site could
have led to information bias. Therefore, replication studies in
external datasets are warranted. Another limitation of this study
that warrants further investigation is the difference in CVD
mortality rates between classes. Numbers in categories 2 and 3
were low and hence power was insufficient to examine in detail
the different causes for the excess CVDmortality rates in Class 3
compared with Class 1. Moreover, our results might be
influenced by confounding by unmeasured risk factors, for
example, those due to under-recording of pre-existing comor-
Table 2
Crude incidence rates and adjusted odds ratios (95% confidence interval) for cardiovascular mortality by latent class (phenotypes).
N Incidence rate (95% CI), % Odds ratio (95% CI)
Model 1 Model 2
Class 1 291 10.3 (9.2–11.5) Reference Reference
Class 2 41 10.0 (7.3–13.3) 0.97 (0.90–1.04) 0.96 (0.87–1.06)
Class 3 37 15.7 (11.3–21.0) 1.60 (1.48–1.73) 1.22 (1.09–1.35)
Model 1: adjusted for age, and gender.
Model 2: adjusted for co-variables presented in Table 1.
CI = confidence interval, N = number of cardiovascular deaths.
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bidities and their duration. The duration of reduced renal
function would be a particularly important measure prone to
under-estimation. Third, we lacked data on lifestyle factors,
including smoking, drinking, and physical activity, although
reliability of such measures is always a potential concern.
Fourth, we did not adjust for PD patients’ socioeconomic status
which could influence patient treatment/management and
general health status. Finally, the proportion of clinical
measurement data that was missing was relatively high,
requiring multiple imputation, which suggesting that further
replication in the external dataset are warranted.
5. Conclusions
In conclusion, a consistently similar high ratio of D2/D0 and D4/
D0 was associated with a high risk of future CVD mortality.
Latent class analysis seems to be a promising method to reveal
otherwise unidentified subgroups that do not fit into the risk
category defined by D4/Do alone. However, in view of the
potential bias due to unmeasured confounders (eg, Family history
of CVDs, and dietary patterns) and the involvement of a single
recruitment site, this association should be further validated in
other external cohorts.
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